Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M). The key difference: IDEXX Laboratories, Inc. is far larger — about 58× YieldMax TSLA Option Income Strategy ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 338,271). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| IDXX | TSLY | |
|---|---|---|
Market Cap | $40.43B | $697.51M |
Volume | 692,164 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $43.35 |
52-Week Low | $504.70 | $20.49 |
Typical Hold Time | 46 Days | 43 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
TSLY trades at $22.45, down 0.66% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent analysis highlights concerns about missing Tesla's upside potential. Support levels cluster around $22 with resistance at $23-24, while RSI indicators remain neutral.
The outlook remains mixed with high yield appeal balanced against structural limitations in capturing Tesla's gains. Key risks include Tesla's volatility regime changes and the ETF's option income strategy constraints. Recent analyst downgrades to Hold reflect diminished upside capture potential amid Tesla's extended capex cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
